Начало・Списък с акции・Camurus AB

Camurus AB

Затворен

612.5 -2.16

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

601.5

Максимум

627.5

Ключови измерители
By Trading Economics
Приходи	53M 292M
Продажби	117M 676M
P/E Средно за сектора	51.827 77.256
EPS	4.08
Марж на печалбата	43.235
Служители	267
EBITDA	54M 315M

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-3.6B 37B
Предишно отваряне	614.66
Предишно затваряне	612.5

Camurus AB Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

11.11.2025 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Mineral Resources Sells Stake in Lithium Mines to Posco For $765 Million

11.11.2025 г., 22:21 ч. UTC

Печалби

Aristocrat Boosts Dividend as Annual Profit Rises 12%

11.11.2025 г., 23:52 ч. UTC

Пазарно говорене

Gold Rises Amid Fed Rate-Cut Prospects -- Market Talk

11.11.2025 г., 23:44 ч. UTC

Печалби

Singtel's 1H Net Profit Surges

11.11.2025 г., 23:42 ч. UTC

Пазарно говорене

Nikkei May Trade Rangebound Amid Caution over U.S. Econ Strength -- Market Talk

11.11.2025 г., 23:18 ч. UTC

Печалби

Singtel: Expects FY Operating Company EBIT to Grow Between High Single Digits and Low Double Digits Vs. Earlier Guidance of High Single-Digit Growth >Z74.SG

11.11.2025 г., 23:15 ч. UTC

Печалби

Singtel: Interim Dividend of 8.2 Singapore Cents per Share, up 17% >Z74.SG

11.11.2025 г., 23:14 ч. UTC

Печалби

Singtel 1H Underlying Net Profit S$1.35B, Up 14% >Z74.SG

11.11.2025 г., 23:12 ч. UTC

Печалби

Singtel 1H Net Exceptional Gain of S$2.05B >Z74.SG

11.11.2025 г., 23:11 ч. UTC

Печалби

Singtel 1H Net S$3.40B Vs. Net S$1.23B >Z74.SG

11.11.2025 г., 23:10 ч. UTC

Печалби

Singtel 1H Rev S$6.91B Vs. S$6.99B >Z74.SG

11.11.2025 г., 23:04 ч. UTC

Пазарно говорене

RBA Will Sharply Focus On Australian Jobs Report -- Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

11.11.2025 г., 21:50 ч. UTC

Пазарно говорене

Печалби

Health Care Roundup: Market Talk

11.11.2025 г., 21:46 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Private Equity Can Benefit From 'Deal-Friendly' Antitrust Policies -- Market Talk

11.11.2025 г., 21:41 ч. UTC

Печалби

Aristocrat: Continues to Actively Pursue Strategic M&A Opportunities

11.11.2025 г., 21:40 ч. UTC

Печалби

Aristocrat: Expects to Deliver Npata Growth Over FY 2026 on a Constant Currency Basis

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Interactive Delivered Revenue Growth Mainly Due to Inclusion of NeoGames

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Key Social Casino Franchises Continued to Outperform Market

11.11.2025 г., 21:39 ч. UTC

Печалби

Aristocrat: Gaming Unit Continued to Deliver Market Share Gains

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: FY Normalized Npata Up 9% in Constant Currency

11.11.2025 г., 21:38 ч. UTC

Печалби

Aristocrat: Final Dividend 49 Australian Cents/Share

11.11.2025 г., 21:37 ч. UTC

Печалби

Aristocrat: FY Statutory Net Profit from Continuing Ops A$1.18 Bln, Up 2.9%

11.11.2025 г., 21:36 ч. UTC

Печалби

Aristocrat: FY Normalized Operating Revenue A$6.3 Bln, Up 11%

11.11.2025 г., 21:35 ч. UTC

Печалби

Aristocrat: FY Normalized Npata A$1.55 Bln, Up 12.2%

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Adj EPS 79c >ALC

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q Rev $2.61B >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon Backs 2025 EPS $3.05-EPS $3.15 >ALC.EB

11.11.2025 г., 21:35 ч. UTC

Печалби

Alcon 3Q EPS 48c >ALC.EB

11.11.2025 г., 21:34 ч. UTC

Печалби

Alcon Backs 2025 Adj EPS $3.05-Adj EPS $3.15 >ALC

Camurus AB Прогноза

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Camurus AB

Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain and Brixadi to treat opioid use disorder. Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; and Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity, as well as licensing agreement with Solasia Pharma. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.

Camurus AB

Преглед

Промяна на цената на акция

Ключови измерители

Пазарни показатели

Camurus AB Графика

Свързани новини

Camurus AB Прогноза

Финанси

Относно Camurus AB